Background: Mild Cognitive Impairment (MCI) and Mild Behavioral Impairment (MBI) represent transitional states between normal aging and incipient dementia. We examined whether presence of cognitive complaint (CC), MCI, and MBI differentially predicted risk for all-cause dementia or Alzheimer's disease (AD) in a population-based sample.
Method: Participants included 598 older adults [55% female, with mean (SD) age = 78.84 (7.51) years] without dementia at baseline of the Cache County Study on Memory in Aging. All completed a clinical assessment and were followed in subsequent waves until dementia diagnosis or non-participation, for a maximum follow-up time of 12 years. MCI classification was based on neuropsychological assessment with test scores falling 1.5 SD < mean on a single measure or 1.0 SD < mean on multiple measures per cognitive domain, according to aged-based norms. CC was based on informant report of difficulties in memory, orientation, judgment, social functioning, home-based activities, language, and recognition of others. MBI was based on the Neuropsychiatric Inventory (NPI), supplemented with informant interview. Participants were categorized as positive/negative for CC, MCI, or MBI only, or in combination; those negative on all three attributes served as the reference category. Separate Cox regression models examined CC-MCI-MBI status and time to all-cause dementia/AD or right censoring, covarying age, sex, education, and APOE ε4 status.
Result: One hundred fifty-six individuals developed dementia (118 AD). Compared to the reference category, MCI only [Hazard Ratio HR (95% CI) = 3.51 (1.49 - 8.22)], CC+MCI [HR (95%CI) = 5.24 (2.33 - 11.79), CC+MBI [HR (95%CI) = 5.29 (1.96 - 14.32)], MCI+MBI [HR (95%CI) = 4.31 (1.24 - 14.94), and CC+MCI+MBI [HR (95%CI) = 17.11 (7.58 - 38.65)] were associated with increased risk of dementia whereas MBI only or CC only was not. For AD, results were similar, except that MCI+MBI was not associated with increased risk (p = .165).
Conclusion: The presence of MCI with or without cognitive complaint or in combination with MBI predicted future AD or all-cause dementia. However, MBI was predictive only in combination with cognitive complaint/MCI. These results emphasize the importance of conducting both cognitive and behavioral assessments to buttress reports of cognitive concerns.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.086971 | DOI Listing |
Sci Rep
January 2025
Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510260, Guangdong, China.
The neutrophil-to-lymphocyte ratio (NLR) may predict outcomes in end-stage liver disease, but its value after transjugular intrahepatic portosystemic shunt (TIPS) is unclear. This study explored the link between NLR and long-term outcomes in decompensated cirrhosis patients post-TIPS. We retrospectively analyzed 184 patients treated between January 2016 and December 2021, noting demographic data, lab results, and follow-up outcomes, including liver transplantation or death.
View Article and Find Full Text PDFCardiovasc Diabetol
January 2025
Department of Cardiology, Rigshospitalet, Copenhagen University Hospital, Inge Lehmanns Vej 7, Copenhagen, 2100, Denmark.
Background: Glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment reduces cardiovascular events in type 2 diabetes. Yet, the impact of GLP-1RA treatment before ST-segment elevation myocardial infarction (STEMI) on long-term prognosis in patients with type 2 diabetes remains unclear. In patients with STEMI and type 2 diabetes, we aimed to investigate the association between long-term prognosis and GLP-1RA treatment before STEMI.
View Article and Find Full Text PDFJ Immunother Cancer
January 2025
Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Background: Immune checkpoint inhibitors (ICIs) are recommended to treat patients with deficient mismatch repair/microsatellite instability high (dMMR/MSI-H) metastatic colorectal cancer (mCRC). Pivotal trials have fixed a maximum ICI duration of 2 years, without a compelling rationale. A shorter treatment duration has the potential to improve patients' quality of life and reduce both toxicity and cost without compromising efficacy.
View Article and Find Full Text PDFBMJ Open Gastroenterol
January 2025
Department of Gastroenterology, Hepatology and Transplant Medicine, University of Duisburg-Essen, Essen, Germany
Objective: Secondary sclerosing cholangitis (SSC) represents a disease with a poor prognosis increasingly diagnosed in clinical settings. Notably, SSC in critically ill patients (SSC-CIP) is the most frequent cause. Variables associated with worse prognosis remain unclear.
View Article and Find Full Text PDFAcad Radiol
January 2025
University Medical Imaging Toronto, Joint Department of Medical Imaging, University Health Network-Sinai Health System -Women's College Hospital, University of Toronto, Toronto, ON, Canada (S.A.M., P.V.H., U.M., A.B.D.). Electronic address:
Rationale And Objectives: Recently, the Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0) was proposed to better evaluate treatment response in prostate cancer patients using PET/CT with prostate-specific membrane antigen (PSMA) than more traditional approaches like metabolic PET evaluation response criteria in solid tumor (PERCIST 1.0).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!